Equities analysts predict that Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will post sales of $75.70 million for the current quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Neurocrine Biosciences’ earnings, with the lowest sales estimate coming in at $57.00 million and the highest estimate coming in at $84.60 million. The company is scheduled to report its next quarterly earnings results on Tuesday, February 13th.

According to Zacks, analysts expect that Neurocrine Biosciences will report full-year sales of $75.70 million for the current financial year, with estimates ranging from $65.10 million to $151.67 million. For the next financial year, analysts expect that the business will post sales of $315.26 million per share, with estimates ranging from $196.30 million to $511.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that cover Neurocrine Biosciences.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Wednesday, November 1st. The company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.49) by $0.36. The firm had revenue of $60.77 million for the quarter, compared to analysts’ expectations of $29.38 million. During the same quarter in the previous year, the company earned ($0.43) EPS.

A number of equities research analysts have recently commented on NBIX shares. Needham & Company LLC reiterated a “buy” rating and set a $58.00 price target on shares of Neurocrine Biosciences in a report on Sunday, September 17th. Robert W. Baird restated an “outperform” rating and issued a $66.00 target price on shares of Neurocrine Biosciences in a report on Thursday, September 21st. Jefferies Group restated a “buy” rating and issued a $69.00 target price (up previously from $66.00) on shares of Neurocrine Biosciences in a report on Tuesday, October 3rd. BMO Capital Markets restated an “outperform” rating and issued a $84.00 target price on shares of Neurocrine Biosciences in a report on Thursday, October 5th. Finally, Leerink Swann restated an “outperform” rating and issued a $72.00 target price (up previously from $67.00) on shares of Neurocrine Biosciences in a report on Tuesday, October 10th. One investment analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $81.13.

In related news, Director Gary A. Lyons sold 10,000 shares of Neurocrine Biosciences stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $72.92, for a total transaction of $729,200.00. Following the completion of the sale, the director now owns 272,066 shares in the company, valued at approximately $19,839,052.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Darin Lippoldt sold 15,237 shares of Neurocrine Biosciences stock in a transaction dated Friday, December 28th. The shares were sold at an average price of $75.00, for a total transaction of $1,142,775.00. Following the sale, the insider now owns 28,394 shares of the company’s stock, valued at approximately $2,129,550. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 116,405 shares of company stock valued at $8,588,519. 4.80% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company lifted its holdings in Neurocrine Biosciences by 7.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock valued at $123,000 after buying an additional 193 shares in the last quarter. Comerica Bank bought a new stake in Neurocrine Biosciences during the 3rd quarter valued at about $210,000. Trexquant Investment LP bought a new stake in Neurocrine Biosciences during the 3rd quarter valued at about $246,000. World Asset Management Inc bought a new stake in Neurocrine Biosciences during the 3rd quarter valued at about $246,000. Finally, Stifel Financial Corp bought a new stake in Neurocrine Biosciences during the 3rd quarter valued at about $246,000.

Shares of Neurocrine Biosciences (NASDAQ NBIX) opened at $81.73 on Friday. Neurocrine Biosciences has a fifty-two week low of $38.43 and a fifty-two week high of $83.57. The company has a current ratio of 14.38, a quick ratio of 14.37 and a debt-to-equity ratio of 1.05.

ILLEGAL ACTIVITY NOTICE: “$75.70 Million in Sales Expected for Neurocrine Biosciences, Inc. (NBIX) This Quarter” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/06/75-70-million-in-sales-expected-for-neurocrine-biosciences-inc-nbix-this-quarter-2.html.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Get a free copy of the Zacks research report on Neurocrine Biosciences (NBIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.